Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma [2]

Journal of the National Cancer Institute

Volumn 91, Issue 20, 1999, Pages 1779-1780

  Fracasso, Paula M ^a,d   Tan Jr , Benjamin R ^a   Grieff, Marvin ^a   Stephenson Jr , Joseph ^b   Liapis, Helen ^a   Umbeck, Nancy L ^a   Von Hoff, Daniel D ^b   Rowinsky, Eric K ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c CTRC Institute for Drug Development   (United States)

^d Box 8056 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; DOXORUBICIN; ELACRIDAR; FUROSEMIDE; GEMCITABINE; LACTATE DEHYDROGENASE; NAVELBINE; PREDNISONE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ADULT; CANCER CHEMOTHERAPY; CASE REPORT; DOSE RESPONSE; EDEMA; HEMATURIA; HUMAN; HYPERTENSION; LETTER; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL;

EID: 0033589285     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.20.1779     Document Type: Letter

References (7)

1. Eagen JW and Lewis EJ. Glomerulopathies of neoplasia. Kidney Int 1977;11:297-306.
2. Alpers CE and Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986;30:465-73.
3. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anticancer Drugs 1998;9: 191-201.
4. Gietema JA, Groen HJM, Meijer S, Smit EF. Effects of gemcitabine on renal function in patients with non-small cell lung cancer. Eur J Cancer 1998;34:199-202.
5. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999;33:555-62.
6. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994;21(5 Suppl 10):42-7.
7. Stephenson J Jr, Aylesworth C, Johnson T, Atkins M, Rinaldi D, Burris H, et al. A phase I study of gemcitabine plus vinorelbine on an every other week schedule. Proc Am Soc Clin Oncol 1998;17:253a.